| 9.525 0.165 (1.76%) | 01-23 15:15 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 11.77 | 1-year : | 13.75 |
| Resists | First : | 10.07 | Second : | 11.77 |
| Pivot price | 8.99 | |||
| Supports | First : | 9.02 | Second : | 8.36 |
| MAs | MA(5) : | 9 |
MA(20) : | 9.17  |
| MA(100) : | 8.86 |
MA(250) : | 8.93 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 72.1 |
D(3) : | 46.9 |
| RSI | RSI(14): 56.4 |
|||
| 52-week | High : | 10.43 | Low : | 7.44 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TBPH ] has closed below upper band by 17.0%. Bollinger Bands are 54.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 9.46 - 9.5 | 9.5 - 9.53 |
| Low: | 8.85 - 8.89 | 8.89 - 8.93 |
| Close: | 9.29 - 9.36 | 9.36 - 9.42 |
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
Sat, 18 Jan 2025
Barclays PLC Has $529,000 Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat
Thu, 16 Jan 2025
Zacks Research Issues Optimistic Estimate for TBPH Earnings - MarketBeat
Tue, 07 Jan 2025
Analysts Are Optimistic We'll See A Profit From Theravance Biopharma, Inc. (NASDAQ:TBPH) - Yahoo Finance
Tue, 17 Dec 2024
Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference - PR Newswire
Tue, 17 Dec 2024
Theravance Biopharma to Meet Investors at J.P. Morgan Healthcare Conference 2025 - StockTitan
Wed, 11 Dec 2024
The past five years for Theravance Biopharma (NASDAQ:TBPH) investors has not been profitable - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 49 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 5.8 (%) |
| Held by Institutions | 96.7 (%) |
| Shares Short | 4,070 (K) |
| Shares Short P.Month | 4,850 (K) |
| EPS | -1.03 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.78 |
| Profit Margin | -78.2 % |
| Operating Margin | -55 % |
| Return on Assets (ttm) | -6.5 % |
| Return on Equity (ttm) | -22.9 % |
| Qtrly Rev. Growth | 7.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.28 |
| EBITDA (p.s.) | -0.78 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -9.2 |
| PEG Ratio | 0 |
| Price to Book value | 2.49 |
| Price to Sales | 7.36 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|